Validation of HPV assays usable in primary screening
Tuesday, December 4, 2018
Main Scientific Session
•
MSS 06
•
10:15 AM
>
11:45 AM
•
Validation of HPV assays usable in primary screening
•
Auditorium I
With implementation of primary HPV screening in several countries, and a growing number of manufacturers marketing HPV assays for screening, the inevitable question will be: Which HPV assays are validated for use in screening, and which comparator assays are relevant for future validation of novel HPV assays?
This session is aimed at facilitating a broad presentation and discussion on assays validation criterions for intended for use in cervical screening as well as the impact of sample collection media on assay performance.
10:15 AM
•
MSS 06-01
•
Principles of validation: Meijer, VALGENT, and FDA
>
M.
Marc
ARBYN
10:30 AM
•
MSS 06-02
•
Challenges in validation: The comparator assay challenge
>
J.
Joakim
DILLNER
10:45 AM
•
MSS 06-03
•
Assays validated on ThinPrep media in Valgent-3
>
M.
Mario
POLJAK
11:00 AM
•
MSS 06-04
•
Assays validated on SurePath media in Valgent-4
>
D.
Ditte Møller
Ejegod,
L.
Lan
XU
11:15 AM
•
MSS 06-05
•
Challenges in validation: sample collection media
>
J.
Jesper
BONDE
11:30 AM
•
MSS 06-06
•
Discussion
|